NewTimeSpace News:As of 13:37 on February 10, 2026, the CSI Medical Index (399989) rose 0.62%. Among its constituent stocks, Levitt Medical Co., Ltd. gained 5.94%, Hotgen Biotech Co., Ltd. 3.60%, Furui Medical Technology Co., Ltd. 3.30%, WuXi AppTec Co., Ltd. 2.59%, and Tigermed Consulting Co., Ltd. 2.59%.GF CSI Medical Service ETF (560260) climbed 0.44% to RMB 0.91. Over a longer horizon, as of February 9, 2026, the ETF had a cumulative gain of 3.32% in the past week, ranking 2nd among 4 comparable funds in terms of growth rate. (The stocks listed above are merely constituent stocks of the index and do not constitute specific investment recommendations.)

In terms of liquidity,GF CSI Medical Service ETF posted an intraday turnover rate of 0.27% with a trading volume of RMB 4.3197 million. As of February 9, the ETF's average daily trading volume in the past month reached RMB 15.0738 million.

In terms of scale,GF CSI Medical Service ETF's size increased by RMB 36.8715 million in the past week, achieving significant growth and ranking 2nd among 4 comparable funds in terms of new scale added. (Data source: Wind)

In terms of share count, the latest share count ofGF CSI Medical Service ETF hit 1.766 billion shares, a one-month high. (Data source: Wind)

In terms of net capital inflows,GF CSI Medical Service ETF has registered consecutive net capital inflows for four consecutive days, with a maximum single-day net inflow of RMB 9.7850 million, a total capital inflow of RMB 17.0014 million and an average daily net inflow of RMB 4.2504 million. (Data source: Wind)

Data shows that leveraged capital has been continuously building positions in the ETF.GF CSI Medical Service ETF has seen net purchases by leveraged capital for three consecutive days, with a maximum single-day net purchase of RMB 1.4247 million, and its latest margin trading balance stood at RMB 8.5356 million. (Data source: Wind)

As of February 9, the net asset value ofGF CSI Medical Service ETF had risen 3.20% over the past two years. In terms of profitability, as of February 9, 2026, since its inception, the ETF has achieved a maximum monthly return of 29.94%, a streak of 5 consecutive months of gains with a cumulative increase of 24.01%, and an average monthly return of 6.78% in upward months. As of February 9, 2026, the ETF has an annualized excess return of 1.57% over the benchmark since its establishment.

In terms of drawdown, as of February 9, 2026,GF CSI Medical Service ETF has a relative benchmark drawdown of 0.04% since the start of the year, representing a relatively low drawdown risk among comparable funds.

Regarding fees,GF CSI Medical Service ETF has a management fee rate of 0.50% and a custodian fee rate of 0.05%, placing it at a relatively low fee level among comparable funds.

In terms of tracking accuracy, as of February 9, 2026,GF CSI Medical Service ETF has a tracking error of 0.014% in the past two months, boasting the highest tracking accuracy among comparable funds.

GF CSI Medical Service ETF closely tracks the CSI Medical Index, which selects listed securities of pharmaceutical and health industry companies engaged in medical device manufacturing, medical services, medical informatization and other medical-themed businesses as index samples, so as to reflect the overall performance of medical-themed listed company securities.

Data shows that as of January 30, 2026, the top 10 weighted stocks of the CSI Medical Index (399989) are WuXi AppTec Co., Ltd., Mindray Medical International Limited, United Imaging Healthcare Co., Ltd., Aier Eye Hospital Group Co., Ltd., Tigermed Consulting Co., Ltd., Pharmaron Beijing Co., Ltd., Yuwell Medical Equipment & Supply Co., Ltd., Lepu Medical Technology (Beijing) Co., Ltd., Meinian Onehealth Healthcare Holdings Co., Ltd. and New Industries Biomedical Engineering Co., Ltd., accounting for a total of 50.64% of the index's weight. (The stocks listed above are merely constituent stocks of the index and do not constitute specific investment recommendations.)

Kaiyuan Securities stated that the implementation of the Medical and Health Basic Strengthening Project has brought new development opportunities for the primary medical care market. On September 7, 2025, the State Council approved the Implementation Plan for the Medical and Health Basic Strengthening Project, a systematic national strategic deployment to "strengthen the grassroots, consolidate the foundation and guarantee basic medical care". This marks the entry of primary medical care development into a new stage, shifting from passively making up for shortcomings to proactively building a system, and from scattered resource sinking to systematic capacity restructuring.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.